- Thinly-traded nano cap CorMedix (NASDAQ:CRMD +37.7%) jumps on a 5x surge in volume in response to its announcement that the FDA has designated its lead product candidate, Neutrolin Catheter Lock Solution, a Qualified Infectious Disease Product (QIDP) for oncology, hemodialysis and ICU patients where catheter-related blood stream infections and clotting can be life-threatening.
- Among the benefits of QIDP status is Fast Track review of the New Drug Application (NDA) and a five-period of market exclusivity, if approved.